1,516
Participants
Start Date
June 8, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
January 31, 2027
SL-BUP
Daily dosing of sublingual buprenorphine-naloxone
XR-BUP
Weekly/monthly dosing of extended-release injectable buprenorphine
XR-NTX
Monthly dosing of extended-release injectable naltrexone
MM
MM consists of standard Medical Management and the usual counseling at the treatment program.
MMR
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
MMD
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
Bellevue Hospital Center, New York
Center for Psychiatric and Chemical Dependency Services (CPCDS), Pittsburgh
Internal Medicine Recovery Engagement Program (IM-REP), Pittsburgh
Mountain Manor / Maryland Treatment Centers, Baltimore
Chestnut Ridge Center, Morgantown
Shoreline Behavioral Health Services, Conway
Gateway Community Services, Jacksonville
Aspire Health Partners, Orlando
Operation PAR, Clearwater
Gibson Center for Behavioral Change, Cape Girardeau
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST), Little Rock
Huntsman Mental Health Institute / University of Utah, Salt Lake City
University of New Mexico Addiction and Substance Abuse Program, Albuquerque
Tarzana Treatment Centers, Inc., Tarzana
Adapt Integrated Health Care, Roseburg
Adapt Integrated Health Care, Winston
Liberation Programs, Inc., Bridgeport
McLean Hospital, Belmont
Stanley Street Treatment and Resources, Inc., Fall River
Square Medical Group, LLC, Newton
Dartmouth Hitchcock - ATP, Lebanon
New York State Psychiatric Institute
OTHER
Columbia University
OTHER
Harvard Medical School (HMS and HSDM)
OTHER
Mclean Hospital
OTHER
National Institute on Drug Abuse (NIDA)
NIH
The Emmes Company, LLC
INDUSTRY
NYU Langone Health
OTHER